Stelara 90 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FCFA5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,584
Award facts
- Contract value 100% obligated
- $16,584.13 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,584.13 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Stelara 90 mg/ml syringes. This firm fixed-price delivery order, issued on December 12, 2025, with an ultimate completion date of January 6, 2026, contains no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group will perform the work at its Park Ridge facility and deliver the pharmaceutical product to support Department of Defense medical supply requirements.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.999 billion contract awarded on November 13, 2025, that extends through December 31, 2036. The PPV-G GEN V represents a component of the broader $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors supplying comprehensive pharmaceutical and medical consumable products to military healthcare facilities worldwide. As a critical supplier within the federal pharmaceutical supply chain, DMS Pharmaceutical Group has demonstrated substantial federal contracting activity and maintains established performance across diverse therapeutic categories including specialty biologics, oncology treatments, and routine pharmaceuticals.
Quick answers
Who was awarded contract SPE2DR26FCFA5?
SPE2DR26FCFA5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 12, 2025.
How much is contract SPE2DR26FCFA5 worth?
The government has obligated $16,584 on SPE2DR26FCFA5.
Is contract SPE2DR26FCFA5 an order under another contract?
Yes. SPE2DR26FCFA5 is a delivery order under SPE2DR25D9130, an indefinite delivery contract.
Was contract SPE2DR26FCFA5 competed?
The extent of competition for SPE2DR26FCFA5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award